Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma
Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma
复制标题
DOI：
10.1002/lary.28142
复制
发表时间：
2020-05
期刊：
影响因子：
--
通讯作者：
Tomoyoshi Sanada;Afsana Islam;Teppei Kaminota;Yui Kirino;Reina Tanimoto;Hana Yoshimitsu;Hajime Yano;Y. Mizuno;Masahiro Okada;Souhei Mitani;Tohru Ugumori;Junya Tanaka;N. Hato
中科院分区：
文献类型：
--
作者：
Tomoyoshi Sanada;Afsana Islam;Teppei Kaminota;Yui Kirino;Reina Tanimoto;Hana Yoshimitsu;Hajime Yano;Y. Mizuno;Masahiro Okada;Souhei Mitani;Tohru Ugumori;Junya Tanaka;N. Hato
据推测，分泌酶赖氨酰氧化酶样2（LOXL 2）通过其在细胞外基质重塑和上皮-间质转化中的功能促进肿瘤进展。我们先前在小鼠淋巴结转移模型中鉴定了转移性人头颈部鳞状细胞癌（HNSCC）细胞中LOXL 2的表达升高。在这里，我们进行了一项病例系列研究，检查了来自HNSCC患者的人血清中的L0 XL 2表达水平，以评估L0 XL 2是否值得在大型队列研究中进行评估。
The secretory enzyme lysyl oxidase like 2 (LOXL2) is speculated to contribute to tumor progression through its functions in the remodeling of extracellular matrix and epithelial‐mesenchymal transition. We previously identified elevated expression of LOXL2 in metastatic human head and neck squamous cell carcinoma (HNSCC) cells in a mouse lymph node metastases model. Here we performed a case series study examining LOXL2 expression levels in human serum from HNSCC patients to evaluate whether LOXL2 is worth evaluation in a large cohort study.